June is Alzheimer’s & Brain Awareness Month, an opportunity to focus on the ongoing research into Alzheimer’s disease (AD) and progressive neurodegenerative disorders. Studies have highlighted the significant role of High-Mobility Group Box 1 (HMGB1) in AD, providing new insights and potential therapeutic applications.
A recent study has explored the dynamic changes in HMGB1 localization within the brain. It was observed that in Alzheimer’s models, HMGB1 is translocated from the nucleus to the cytoplasm in neurons and microglia, promoting its extracellular secretion and contributing to the disease pathology.
Another research reveals that trilobatin, a natural compound, significantly improves cognitive function in AD models. This effect is achieved by targeting HMGB1 and modulating the SIRT3/SOD2 signaling pathway, which restores redox homeostasis and reduces neuroinflammation. The study demonstrated that trilobatin binds directly to HMGB1, inhibiting its harmful interactions and leading to improved cognitive outcomes in animal models.
These findings emphasize the potential of HMGB1 as a biomarker and a target for new treatments aimed at mitigating neuroinflammatory processes in Alzheimer’s disease.
Understanding and targeting HMGB1 in neurodegenerative disorders could bring researches to innovative therapeutic strategies. At HMGBiotech, we are dedicated to advancing research and providing comprehensive information on HMGB1 protein.
Contact us for your pre-sales questions about HMGB1
Read the full articles about the studies:
https://pubmed.ncbi.nlm.nih.gov/38247880
https://pubmed.ncbi.nlm.nih.gov/35292770
